HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,926,236 | -16.4% | 77,319 | -20.5% | 0.01% | -10.0% |
| Q2 2023 | $8,285,315 | +155.6% | 97,314 | +148.4% | 0.01% | +150.0% |
| Q1 2023 | $3,241,400 | +111.1% | 39,171 | +100.6% | 0.00% | +100.0% |
| Q4 2022 | $1,535,641 | +4.4% | 19,525 | -1.7% | 0.00% | 0.0% |
| Q3 2022 | $1,470,532 | -47.5% | 19,864 | -53.8% | 0.00% | -71.4% |
| Q2 2022 | $2,801,000 | +122.7% | 42,976 | +115.9% | 0.01% | +133.3% |
| Q1 2022 | $1,258,000 | +20.8% | 19,902 | +1.4% | 0.00% | +50.0% |
| Q4 2021 | $1,041,000 | -94.2% | 19,628 | -92.3% | 0.00% | -94.4% |
| Q3 2021 | $17,946,000 | +5.8% | 254,230 | -0.2% | 0.04% | +9.1% |
| Q2 2021 | $16,970,000 | -23.5% | 254,650 | +27.4% | 0.03% | -26.7% |
| Q1 2021 | $22,184,000 | -19.3% | 199,831 | -13.6% | 0.04% | -19.6% |
| Q4 2020 | $27,473,000 | +28.8% | 231,354 | -5.3% | 0.06% | +19.1% |
| Q3 2020 | $21,322,000 | +12.9% | 244,384 | +15.9% | 0.05% | +6.8% |
| Q2 2020 | $18,887,000 | -20.4% | 210,886 | -11.4% | 0.04% | -31.2% |
| Q1 2020 | $23,721,000 | +9.1% | 238,018 | +25.8% | 0.06% | +42.2% |
| Q4 2019 | $21,747,000 | -26.3% | 189,264 | -19.1% | 0.04% | -30.8% |
| Q3 2019 | $29,508,000 | +2.9% | 233,923 | -1.9% | 0.06% | +4.8% |
| Q2 2019 | $28,684,000 | +444.7% | 238,354 | +295.9% | 0.06% | +416.7% |
| Q1 2019 | $5,266,000 | -14.9% | 60,200 | -2.7% | 0.01% | -20.0% |
| Q4 2018 | $6,190,000 | -16.2% | 61,869 | -4.1% | 0.02% | 0.0% |
| Q3 2018 | $7,388,000 | +163.3% | 64,481 | +106.1% | 0.02% | +150.0% |
| Q2 2018 | $2,806,000 | +15.3% | 31,291 | -6.0% | 0.01% | +20.0% |
| Q1 2018 | $2,434,000 | +26.0% | 33,273 | 0.0% | 0.01% | +25.0% |
| Q4 2017 | $1,932,000 | +29.4% | 33,273 | 0.0% | 0.00% | +33.3% |
| Q3 2017 | $1,493,000 | +60.9% | 33,273 | +41.5% | 0.00% | +50.0% |
| Q2 2017 | $928,000 | +12.9% | 23,510 | +16.0% | 0.00% | 0.0% |
| Q1 2017 | $822,000 | +0.9% | 20,267 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $815,000 | +0.9% | 20,267 | -9.2% | 0.00% | 0.0% |
| Q3 2016 | $808,000 | +24.9% | 22,321 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $647,000 | -17.2% | 22,321 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $781,000 | +8.5% | 22,321 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $720,000 | -0.1% | 22,321 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $721,000 | -96.5% | 22,321 | -95.6% | 0.00% | -95.8% |
| Q2 2015 | $20,761,000 | -18.5% | 501,954 | -11.5% | 0.05% | -15.8% |
| Q1 2015 | $25,483,000 | +2.2% | 567,282 | -14.9% | 0.06% | +3.6% |
| Q4 2014 | $24,936,000 | -0.1% | 666,390 | -6.8% | 0.06% | -3.5% |
| Q3 2014 | $24,973,000 | -1.9% | 715,160 | -0.9% | 0.06% | -1.7% |
| Q2 2014 | $25,464,000 | +6.1% | 721,778 | -2.0% | 0.06% | +5.5% |
| Q1 2014 | $23,998,000 | -24.0% | 736,378 | -1.8% | 0.06% | -24.7% |
| Q4 2013 | $31,593,000 | +6.5% | 749,878 | +0.8% | 0.07% | -1.4% |
| Q3 2013 | $29,654,000 | +3.5% | 743,578 | +7.3% | 0.07% | -6.3% |
| Q2 2013 | $28,659,000 | – | 693,078 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |